Lifevantage (NASDAQ:LFVN) Announces Quarterly Earnings Results

Key Points

• LifeVantage reported quarterly EPS of $0.05, missing the $0.06 consensus estimate, while revenue of $37.12 million fell short of the $40.49 million forecast.
• Analyst sentiment was negative overall: the stock carried a consensus “Reduce” rating and a $5.50 price target, with two Hold ratings and one Sell rating.
• The company paid a quarterly dividend of $0.05 per share, equivalent to an annualized $0.20 and a 3.8% yield.

Lifevantage (NASDAQ:LFVN - Get Free Report) posted its quarterly earnings data on Monday. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.01), FiscalAI reports. Lifevantage had a net margin of 2.78% and a return on equity of 21.56%. The firm had revenue of $37.12 million for the quarter, compared to the consensus estimate of $40.49 million.

Lifevantage Stock Performance

Shares of LFVN traded up $0.07 during mid-day trading on Monday, reaching $5.29. The company had a trading volume of 30,822 shares, compared to its average volume of 216,061. The company has a market capitalization of $66.60 million, a price-to-earnings ratio of 13.22 and a beta of 0.71. The firm has a 50-day moving average price of $6.06 and a 200 day moving average price of $5.88. Lifevantage has a 52 week low of $3.90 and a 52 week high of $11.71.

Lifevantage Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 15th. Stockholders of record on Tuesday, September 1st were given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 3.8%. The ex-dividend date of this dividend was Tuesday, September 1st. Lifevantage's payout ratio is currently 50.00%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on LFVN shares. Zacks Research cut Lifevantage from a "hold" rating to a "strong sell" rating in a research note on Friday, October 16th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Lifevantage in a research note on Friday, August 21st. Finally, Lake Street Capital increased their price objective on Lifevantage from $5.00 to $6.00 and gave the stock a "hold" rating in a report on Friday, August 28th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Reduce" and a consensus price target of $5.50.

Insiders Place Their Bets

In other Lifevantage news, insider Kristen Cunningham sold 8,901 shares of Lifevantage stock in a transaction on Monday, September 14th. The stock was sold at an average price of $6.18, for a total transaction of $55,008.18. Following the completion of the transaction, the insider owned 120,162 shares in the company, valued at approximately $742,601.16. The trade was a 6.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.58% of the stock is currently owned by company insiders.

Lifevantage Company Profile

LifeVantage Corporation is a health and wellness company that develops, markets and distributes dietary supplements and personal-care products. Its product portfolio is designed to support areas such as cellular health, antioxidant defenses, energy, nutrition and skin care.

The company's principal brands have included Protandim, a line of dietary supplements; TrueScience, a skin-care and wellness brand; and Petandim, products formulated for pets. LifeVantage primarily uses a direct-selling business model, distributing its products through independent sales representatives and online channels.

Founded in 2003 and headquartered in Lehi, Utah, LifeVantage serves customers in the United States and selected international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.